Lifeboat Foundation

Our cells perform a marvel of engineering when it comes to packing information into small spaces. Every time a cell divides, it bundles up an amazing 4 metres of DNA into 46 tiny packages, each of which is only several millionths of a metre in length. Researchers from EMBL Heidelberg and the Julius-Maximilians-Universität Würzburg have now discovered how a family of DNA motor proteins succeeds in packaging loosely arranged strands of DNA into compact individual chromosomes during cell division.

The researchers studied condensin, a protein complex critical to the process of chromosome formation. Although this complex was discovered more than three decades ago, its mode of action remained largely unexplored. In 2018, researchers from the Häring group at EMBL Heidelberg and their collaborators showed that condensin molecules create loops of DNA, which may explain how chromosomes are formed. However, the inner workings by which the protein complex achieves this feat remained unknown.

Continue reading “How the Genome Shapes Up for Cell Division” »

A non-profit organization merges engineering and biology to accelerate drug development for childhood cancers.

Summary: A new injectable therapy that uses specially engineered molecules could help treat spinal cord injury.

Source: DOE

A new injectable therapy for spinal cord injuries uses specially engineered molecules that trigger a healing response in spinal cells.

In a new letter, Elon Musk threatens to walk away from $44 Billion Twitter deal if the management doesn’t provide more data on total bot counts.

According to a letter sent by Elon Musk’s legal team to Twitter, “Twitter refused to provide the information that Mr. Musk has repeatedly requested since May 9, 2022 to facilitate his evaluation of spam and fake accounts on the company’s platform” and “It’s effort to characterize it otherwise is merely an attempt to obfuscate and confuse the issue”.

The letter also reminded that Musk does not believe the company’s lax testing methodologies are adequate so he must conduct his own analysis and “The data he has requested is necessary to do so”. The letter also said “Mr. Musk is entitled to seek, and Twitter is obligated to provide information and data”.

A group of photonics researchers at Tampere University have introduced a novel method to control a light beam with another beam through a unique plasmonic metasurface in a linear medium at ultra-low power. This simple linear switching method makes nanophotonic devices such as optical computing and communication systems more sustainable, requiring low intensity of light.

A group of photonics researchers at Tampere University have introduced a novel method to control a light beam with another beam through a unique plasmonic metasurface in a linear medium at ultra-low power. This simple linear switching method makes nanophotonic devices such as optical computing and communication systems more sustainable, requiring low intensity of light.

All–optical switching is the modulation of signal light due to control light in such a way that it possesses the on/off conversion function. In general, a light beam can be modulated with another intense laser beam in the presence of a nonlinear medium.

The switching method developed by the researchers is fundamentally based on the quantum optical phenomenon known as Enhancement of Index of Refraction (EIR).

A study of the Type 2 diabetes drug tirzepatide found it resulted in dramatic weight loss, offering hope for those struggling with obesity.

Elon Musk accused Twitter of “resisting and thwarting” his right to information about fake accounts on the platform, calling it in a letter to the company on Monday a “clear material breach” of the terms of their merger agreement.

“Mr. Musk reserves all rights resulting therefrom, including his right not to consummate the transaction and his right to terminate the merger agreement,” the letter, signed by Skadden Arps attorney Mike Ringler, says.

Twitter shares were down 5% on Monday morning.

A drug combination targeting multiple mutant versions of cancer’s “death star” protein has shown promise in a small, early-phase clinical trial for some patients with advanced lung, ovarian and thyroid cancer.

The two–drug combination was effective against advanced cancers with a range of mutations to the KRAS gene—dubbed the “death star” because its protein drives one in four cancers and has a largely impenetrable, drug-resistant surface.

The phase I trial tested the drugs VS-6766 and everolimus in 30 patients with a range of mutations to KRAS—including 11 with highly advanced, non-small cell lung cancer.